AstraZeneca logo

Associate Director, Translational Medicine Lead

AstraZeneca

Cambridge, MAOnsitePosted 2 days ago$142,377.60 - $213,566.40/year
Full TimeDirector & AboveResearch & ScientistPharmaceutical
Original posting ↗

Summary

We are seeking a highly motivated Associate Director, Translational Medicine Lead to develop and lead hypothesis-driven biomarker strategies and translational science across our B-cell malignancy programs, spanning B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Chronic Lymphocytic Leukemia (B-CLL), and Non-Hodgkin Lymphoma (NHL), including combination therapy studies. The role will translate disease biology and therapeutic mechanism into actionable plans for patient stratification/selection, target engagement, pharmacodynamic assessment, depth and durability of response, and mechanisms of resistance. This is a 100% Translational Medicine role supporting large molecules (T-cell engaging bispecifics, ADCs, monoclonal antibodies), small molecules, and cell-based therapies.

Job description

Role Summary

We are seeking a highly motivated Associate Director, Translational Medicine Lead to develop and lead hypothesis-driven biomarker strategies and translational science across our B-cell malignancy programs, spanning B-cell Acute Lymphoblastic Leukemia (B-ALL), B-cell Chronic Lymphocytic Leukemia (B-CLL), and Non-Hodgkin Lymphoma (NHL), including combination therapy studies. The role will translate disease biology and therapeutic mechanism into actionable plans for patient stratification/selection, target engagement, pharmacodynamic assessment, depth and durability of response, and mechanisms of resistance. This is a 100% Translational Medicine role supporting large molecules (T-cell engaging bispecifics, ADCs, monoclonal antibodies), small molecules, and cell-based therapies.

Key Responsibilities

  • Develop and own translational science strategies for assigned B-cell malignancy programs from preclinical stages through Phase 1/2 and Phase 3 clinical studies.
  • Generate and integrate disease linkage data to support indication selection, patient stratification, and targeted population definition.
  • Measure and interpret target engagement, pharmacodynamic biomarkers, and mechanism of action data to inform dose selection and clinical decision-making.
  • Define and investigate mechanisms of resistance to B-cell targeted therapies using longitudinal and relapse clinical samples.
  • Analyze B-cell tumor biology, cancer pathway interactions, and tumor microenvironment features to guide rational drug combination strategies.
  • Lead development and deployment of fit-for-purpose translational assays (flow cytometry, IHC/IF, molecular, MRD-adjacent panels) internally and through external CRO/laboratory partners.
  • Collaborate with Precision Diagnostics to ensure appropriate sample collection, traceability, and documentation; support CDx pathway discussions.
  • Contribute translational and biomarker content for regulatory interactions and filings.
  • Represent the TM function within program-level cross-functional teams as a scientific partner to Clinical Development, Oncology Research, Clinical Operations, and Product Development.
  • Embed biomarker strategies and translational endpoints into clinical study protocols, sample collection manuals, statistical analysis plans, and data delivery cadences.
  • Contribute to translational strategy across the broader B-cell hematology portfolio.
  • Partner with preclinical discovery teams to ensure translational insights inform early compound selection and target validation.
  • Contribute to and ensure the quality of TM clinical study reports, data reviews, scientific presentations, and recommendations for program governance and Go/No-Go decisions.
  • Integrate translational findings across experiments and studies to build a coherent scientific narrative.
  • Communicate biomarker data clearly to internal stakeholders including program governance forums and leadership teams.
  • Contribute to scientific publications and conference presentations; represent AstraZeneca in external scientific forums.

Required Qualifications

  • Established knowledge of B-cell malignancy biology spanning leukemia (B-ALL, B-CLL) and lymphoma (NHL), including disease pathogenesis, standard-of-care landscape, and mechanisms of therapeutic resistance.
  • In-depth understanding of immunology and the tumor microenvironment in B-cell cancers.
  • Demonstrated experience with T-cell engaging bispecifics (e.g., CD3-targeting bispecifics, BiTEs) in an oncology/hematology development context.
  • Demonstrated experience with antibody-drug conjugates (ADCs) in a hematology or oncology development context.
  • PhD in a relevant biological science (hematology-oncology, immunology, oncology, molecular biology, or related field); postdoctoral and/or industry experience required.
  • 3-5 years experience contributing to early phase oncology clinical trials, including biomarker plan development, protocol input, and sample analysis.
  • Demonstrated expertise in biomarker technologies such as flow cytometry, immunohistochemistry, molecular profiling, NGS, ctDNA, MRD assessment, cytokine/immune profiling, and other omics-based approaches.
  • Emerging understanding of the end-to-end clinical development process and the strategic role of biomarkers at each stage.
  • Ability to work independently and deliver translational programs with regular managerial support.
  • Proven ability to operate effectively and demonstrate scientific leadership within cross-functional program teams in a matrixed pharma or biotech environment.
  • Excellent communication and presentation skills for internal stakeholders and emerging external scientific audiences.

Preferred Qualifications

  • Experience with small molecule hematology therapeutics in B-cell malignancies (e.g., BTK inhibitors, BCL-2 inhibitors) and familiarity with combination treatment strategies.
  • Exposure to cell therapy programs (CAR-T or other engineered cell therapies) in B-cell leukemia or lymphoma.
  • Familiarity with Minimal Residual Disease (MRD) methodologies (flow cytometry and/or NGS-based) in leukemia or lymphoma clinical development.
  • Experience integrating multi-omic biomarker data to support clinical decision-making across combination regimens.
  • Familiarity with regulatory expectations for biomarker analytical validation and CDx development.
  • Early experience mentoring junior scientists; interest in contributing to team capability development.

Requirements

  • Established knowledge of B-cell malignancy biology spanning leukemia (B-ALL, B-CLL) and lymphoma (NHL)
  • In-depth understanding of immunology and the tumor microenvironment in B-cell cancers
  • Demonstrated experience with T-cell engaging bispecifics in oncology/hematology development
  • Demonstrated experience with antibody-drug conjugates (ADCs) in hematology or oncology development
  • PhD in a relevant biological science (hematology-oncology, immunology, oncology, molecular biology, or related field)
  • Postdoctoral and/or industry experience required
  • 3-5 years experience contributing to early phase oncology clinical trials
  • Expertise in biomarker technologies such as flow cytometry, immunohistochemistry, molecular profiling, NGS, ctDNA, MRD assessment, cytokine/immune profiling, and omics-based approaches
  • Understanding of the end-to-end clinical development process
  • Ability to work independently and deliver translational programs
  • Proven ability to demonstrate scientific leadership within cross-functional program teams in a matrixed pharma or biotech environment
  • Excellent communication and presentation skills

Benefits

  • 401(k) Retirement Programs
  • Paid Time Off
  • Health, Dental & Vision Coverage
  • Short-Term Incentive Bonuses
  • Equity-Based Awards

Company overview

AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, and shareholders. With a workforce of over 94,300 employees worldwide, the company operates across three core therapy areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, Respiratory & Immunology), and Rare Disease. Headquartered in Cambridge, UK, AstraZeneca maintains strategic R&D centers in Cambridge, Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing. The company generated $54.1 billion in total revenue in 2024 and invested $13.6 billion in scientific research and development. AstraZeneca's bold aspiration is to be pioneers in science, lead in disease areas, and transform patient outcomes, with a goal to launch 20 new medicines and achieve $80 billion in total revenue by 2030. The company is recognized for its commitment to sustainability, health equity, and creating an inclusive work environment where diverse perspectives drive innovation.

Explore more jobs of your matchFind more biopharma roles with GetBioJob.